Cargando…

Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro

Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavir...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Seri, Kim, Suwon, Kim, Dae Yong, Kim, Mi-Sun, Shin, Dong Hae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470085/
https://www.ncbi.nlm.nih.gov/pubmed/32746637
http://dx.doi.org/10.1080/14756366.2020.1801672
_version_ 1783578515449315328
author Jo, Seri
Kim, Suwon
Kim, Dae Yong
Kim, Mi-Sun
Shin, Dong Hae
author_facet Jo, Seri
Kim, Suwon
Kim, Dae Yong
Kim, Mi-Sun
Shin, Dong Hae
author_sort Jo, Seri
collection PubMed
description Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the good targets to find antiviral agents before vaccines are available. Some flavonoids are known to inhibit 3CLpro from SARS-CoV which causes SARS. Since their sequence identity is 96%, a similar approach was performed with a flavonoid library. Baicalin, herbacetin, and pectolinarin have been discovered to block the proteolytic activity of SARS-CoV-2 3CLpro. An in silico docking study showed that the binding modes of herbacetin and pectolinarin are similar to those obtained from the catalytic domain of SARS-CoV 3CLpro. However, their binding affinities are different due to the usage of whole SARS-CoV-2 3CLpro in this study. Baicalin showed an effective inhibitory activity against SARS-CoV-2 3CLpro and its docking mode is different from those of herbacetin and pectolinarin. This study suggests important scaffolds to design 3CLpro inhibitors to develop antiviral agents or health-foods and dietary supplements to cope with SARS-CoV-2.
format Online
Article
Text
id pubmed-7470085
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74700852020-09-15 Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro Jo, Seri Kim, Suwon Kim, Dae Yong Kim, Mi-Sun Shin, Dong Hae J Enzyme Inhib Med Chem Research Paper Coronavirus disease 2019 (COVID-19) has been a pandemic disease of which the termination is not yet predictable. Currently, researches to develop vaccines and treatments is going on globally to cope with this disastrous disease. Main protease (3CLpro) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the good targets to find antiviral agents before vaccines are available. Some flavonoids are known to inhibit 3CLpro from SARS-CoV which causes SARS. Since their sequence identity is 96%, a similar approach was performed with a flavonoid library. Baicalin, herbacetin, and pectolinarin have been discovered to block the proteolytic activity of SARS-CoV-2 3CLpro. An in silico docking study showed that the binding modes of herbacetin and pectolinarin are similar to those obtained from the catalytic domain of SARS-CoV 3CLpro. However, their binding affinities are different due to the usage of whole SARS-CoV-2 3CLpro in this study. Baicalin showed an effective inhibitory activity against SARS-CoV-2 3CLpro and its docking mode is different from those of herbacetin and pectolinarin. This study suggests important scaffolds to design 3CLpro inhibitors to develop antiviral agents or health-foods and dietary supplements to cope with SARS-CoV-2. Taylor & Francis 2020-08-04 /pmc/articles/PMC7470085/ /pubmed/32746637 http://dx.doi.org/10.1080/14756366.2020.1801672 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Jo, Seri
Kim, Suwon
Kim, Dae Yong
Kim, Mi-Sun
Shin, Dong Hae
Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
title Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
title_full Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
title_fullStr Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
title_full_unstemmed Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
title_short Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
title_sort flavonoids with inhibitory activity against sars-cov-2 3clpro
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470085/
https://www.ncbi.nlm.nih.gov/pubmed/32746637
http://dx.doi.org/10.1080/14756366.2020.1801672
work_keys_str_mv AT joseri flavonoidswithinhibitoryactivityagainstsarscov23clpro
AT kimsuwon flavonoidswithinhibitoryactivityagainstsarscov23clpro
AT kimdaeyong flavonoidswithinhibitoryactivityagainstsarscov23clpro
AT kimmisun flavonoidswithinhibitoryactivityagainstsarscov23clpro
AT shindonghae flavonoidswithinhibitoryactivityagainstsarscov23clpro